Early research (Phase 1)Study completedNCT03551782
What this trial is testing
Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
Who this might be right for
Castration-Resistant Prostatic Neoplasms
Janssen Research & Development, LLC 33